Additional Positive Efficacy Data with BI-1808 monotherapy from Ph 2a anti-TNFR2 program Announced September 17, 2024
Elraglusib Demonstrated Anti-Tumor Activity with Two Ongoing Durable CRs and ~62% DCR in First 8 Patients with R/R Ewing and Ewing-related Sarcomas September 17, 2024
Encouraging results from expansion part of Ph 1/2 SOHO-01 study of BAY 2927088 in advanced HER2-mutant NSCLC announced September 17, 2024
Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced NSCLC September 17, 2024
Median OS of 15.6 months in Ph 2 Bria-IMT™ study patients treated in combination with CPI announced September 17, 2024
FAILED TRIAL: CONTACT-02 Ph 3 mCRC trial did not meet statistical significance of OS endpoint September 17, 2024
Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful PFS announced September 17, 2024
Ph 2 THIO-101 trial results show THIO Followed by Cemiplimab Leads to Potential OS Benefit in Pretreated Advanced NSCLC September 17, 2024
Successful pre-BLA meeting with the US FDA to support BLA for RP1 (vusolimogene oderparepvec) in anti-PD1 failed melanoma via the accelerated approval pathway in 2H 2024 announced September 17, 2024
FDA Clears IND Application for Ph 1/2 Clinical Trial of an AAV-delivered Cancer Immunotherapy, VNX-101 September 17, 2024
Scancell and PharmaJet to use Stratis® IM Needle-free delivery System for SCIB1/iSCIB1+ vaccine for Advanced Melanoma September 17, 2024
